Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Allogene Therapeutics Inc. (Nasdaq: ALLO)

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others. *

 

Period Start 2018-04-03 established (approx)
Products Industry CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
  Industry 2 cell therapy
Person Person Belldegrun, Arie (Allogene 201806 Executive Chairman before Kite Pharma CEO)
     
Region Region South San Francisco, CA
  Country United States (USA)
  Street 270 Littlefield Avenue
  City 94080 South San Francisco, CA
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency USD
  Profit -211,505,000 (2018-12-31)
  Cash 721,350,000 (2018-12-31)
     
    * Document for �About Section�: Allogene Therapeutics, Inc.. (4/3/18). "Press Release: Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio". New York, NY & South San Francisco, CA.
     
   
Record changed: 2020-02-20

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Allogene Therapeutics Inc. (Nasdaq: ALLO)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top